Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Autosomal Dominant Polycystic Kidney Disease: early-phase trial registry
4 of 10 indexed Autosomal Dominant Polycystic Kidney Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Autosomal Dominant Polycystic Kidney Disease: 10 US clinical trials tracked, 4 recruiting.
Autosomal Dominant Polycystic Kidney Disease is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 5 of these trials.
Enrollment posture brief
Registry condition autosomal-dominant-polycystic-kidney-disease
OPEN 4 | RECR 40% | LATE 0 | EARLY 3 | RANK #1724 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)
Autosomal Dominant Polycystic Kidney Disease lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Autosomal Dominant Polycystic Kidney Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Autosomal Dominant Polycystic Kidney Disease is recruiting below its size-band peers.
4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Autosomal Dominant Polycystic Kidney Disease research.
Mayo Clinic accounts for 5 of 10 trials (50%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Autosomal Dominant Polycystic Kidney Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.
-
Autosomal Dominant Polycystic Kidney Disease research leans observational.
3 interventional and 7 observational studies make up this index (30% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
AbbVie
NCT06902558
NOX4 and Related Biomarkers in ADPKD
Mayo Clinic
NCT04630613
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mayo Clinic
NCT04344769
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
AstraZeneca
NCT07228364
Role of ROS and cAMP-PKA Biomarkers in ADPKD
Mayo Clinic
NCT07217158
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
Mayo Clinic
NCT05193981
Intrarenal Microvasculature in ADPKD
Mayo Clinic
NCT05288998
ADPKD Cohort Study
Emory University
NCT02084849
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
University of Pittsburgh
NCT01039987
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
Otsuka Pharmaceutical Development & Commercialization
NCT01210560
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Autosomal Dominant Polycystic Kidney Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Autosomal Dominant Polycystic Kidney Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Autosomal Dominant Polycystic Kidney Disease page
10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Autosomal Dominant Polycystic Kidney Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Autosomal Dominant Polycystic Kidney Disease trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Autosomal Dominant Polycystic Kidney Disease condition card totals 10 registered trials; most-linked intervention Tolvaptan IR; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.